Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determination of Serum Infliximab Concentration by Point‐of‐care Devices in Children With Inflammatory Bowel Disease
Debora Curci, Marianna Lucafò, Adriana Cifù, et al.
Journal of Pediatric Gastroenterology and Nutrition (2019) Vol. 69, Iss. 4, pp. 474-479
Open Access | Times Cited: 19

Showing 19 citing articles:

A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases
W Kantasiripitak, Sebastian G. Wicha, Debby Thomas, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 6, pp. 896-908
Open Access | Times Cited: 21
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease
Raffaella Franca, Debora Curci, Marianna Lucafò, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 7, pp. 527-539
Open Access | Times Cited: 23
Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
Debora Curci, Marianna Lucafò, Adriana Cifù, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 6, pp. 2184-2192
Open Access | Times Cited: 16
Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA
Francisco José Toja-Camba, Laura García‐Quintanilla, Lorena Rodríguez-Martínez, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2615-2615
Open Access | Times Cited: 6
Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
Akshay Kapoor, Eileen Crowley
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 15
Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels
Vasilije Novakovic, Samire Abdija, Pia Bükmann Larsen, et al.
Clinical Biochemistry (2019) Vol. 74, pp. 73-75
Closed Access | Times Cited: 16
Infliximab monitoring in Crohn’s disease: a neural network approach for evaluating disease activity and immunogenicity
Luís Eduardo Miani Gomes, Lívia Moreira Genaro, Marina Moreira de Castro, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress
Debora Curci, Marianna Lucafò, Giuliana Decorti, et al.
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
Tomislav Jukić, David Drobne, Sasa Pusavec, et al.
Medical Science Monitor (2023) Vol. 29
Open Access | Times Cited: 3
Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges
Stefania Cheli, Diego Savino, Francesca Penagini, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1834-1834
Open Access | Times Cited: 3
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Konstantinos Papamichael, Adam S. Cheifetz
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 12, pp. 1423-1431
Closed Access | Times Cited: 7
Therapeutic drug monitoring in Crohn’s disease patients treated with anti-TNF: a comparison of two techniques
Giorgia Bodini, Maria Giulia Demarzo, Afscin Djahandideh Sheijani, et al.
European Journal of Gastroenterology & Hepatology (2021) Vol. 34, Iss. 4, pp. 382-388
Closed Access | Times Cited: 6
Monitoramento terapêutico de Infliximabe na doença de Crohn
Luís Eduardo Miani Gomes
(2024)
Closed Access
Lateral flow test versus enzyme‐linked immunosorbent assay to measure infliximab trough concentrations: A head‐to‐head comparison
Marleen Bouhuys, Margreet Wessels, Willemien de Vries, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024)
Open Access
Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab
Carles Iniesta Navalón, Manuel Ríos-Saorín, Rebeca Añez-Castaño, et al.
Therapeutic Drug Monitoring (2024)
Closed Access
Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels
Dong Xiang, Ninghong Li, Lu Liu, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21858-e21858
Open Access | Times Cited: 1
Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease
Kyle Gress, Julie Bass, Ryan S. Funk, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 3
Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients
Marieke Zijlstra, M Jongsma, Annick de Vries, et al.
Journal of Pediatric Gastroenterology and Nutrition (2020) Vol. 72, Iss. 1, pp. 56-60
Closed Access | Times Cited: 2
Page 1

Scroll to top